INTERLEUKIN-6, ITS SUBUNIT gp 130 AND THE POTENTIAL RISK OF PROSTATE CANCER IN A POPULATION OF MEN FROM TOBAGO by Roman, Lalicia N.
  
INTERLEUKIN-6, ITS SUBUNIT gp 130 AND THE POTENTIAL RISK OF PROSTATE 
CANCER IN A POPULATION OF MEN FROM TOBAGO 
 
by 
Lalicia Roman 
B.S, Chatham College, 1998 
 
Submitted to the Graduate Faculty of 
Graduate School of Public Health in partial fulfillment  
of the requirements for the degree of 
Master of Science 
University of Pittsburgh 
 
2006 
UNIVERSITY OF PITTSBURGH 
 
Graduate School of Public Health 
 
 
This thesis was presented 
 
By 
 
Lalicia N. Roman 
 
It was defended on 
 
April 25, 2006 
 
 
 
 
Thesis Advisor: 
Dr. Robert Ferrell, PhD 
Professor 
Human Genetics 
Graduate School of Public Health 
University of Pittsburgh 
 
Committee Member: 
M. Michael Barmada, PhD 
Associate Professor 
Human Genetics 
Graduate School of Public Health 
University of Pittsburgh 
 
Committee Member: 
Stephen Thomas, PhD 
Professor 
Center for Minority Health 
Graduate School of Public Health 
 
 
 
 
 
 
 
 
ii 
 INTERLEUKIN-6 ITS SUBUNIT gp130 AND THE POTENTIAL RISK OF 
PROSTATE CANCER IN A POPULATION OF MEN FROM TOBAGO 
Lalicia Roman 
University of Pittsburgh, 2006
 
 
Prostate cancer is a public health concern, particularly to the African-American 
community.  African-American men are disproportionately affected and experience prostate 
cancer rates about 60% more often than white Americans.  It is the second leading cancer in men 
and it is second only to lung cancer in cancer related deaths.  This is a significant public health 
problem.  This paper will focus on the gene Interleukin 6 signal transducer isoform 1 (IL6ST), on 
chromosome 5q11.2, with polymorphisms relating to gp130 [rs 3730293 and rs 3729960]; both 
single nucleotide polymorphisms result in an amino acid change.  The change is Glycine to 
Arginine for rs 3729960 which is located in exon 14 and Isoleucine to Threonine for rs 3730293 
which is located in exon 10. Human IL-6 signaling requires the 80kDa IL-6R receptor, which is 
responsible for IL-6 specificity and the 130kDa glycoprotein, gp130, the signal transduction 
subunit for signal transduction to occur.  IL-6 acts through its receptors which are polymorphic, 
and subsequently may cause it to have different functionality.  A population based case/control 
study was conducted to evaluate the influence of gp130 snps on prostate cancer risk in an Afro-
Caribbean male population of Tobago.  This population was chosen because of the high 
prevalence of prostate cancer.  A subset of 1000 samples taken from a study done by Bunker et 
al, was genotyped by PCR and fluorescence polarization methods.  Statistical analysis yielded all 
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estimated allele frequencies to be in Hardy Weinberg Equilibrium.  Chi square analysis of the 
cases and controls yielded no significant association of the gp130 snps and prostate cancer risk. 
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1.0  INTRODUCTION 
Prostate cancer is a disease where by cancer develops in the prostate, a gland in the human male 
reproductive system.  The prostate is a male reproductive organ that both creates and stores 
seminal fluid.  The prostate is a walnut sized gland located in front of the rectum and underneath 
the urinary bladder of men.  
 
 
 
Figure 1:  Diagram showing the position of the prostate gland 
Figure 1 taken from www.liv.ac.uk/researchintelligence/issue21/prostatecancer.html 
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 Clinically evident prostate cancer can be established by tissue diagnosis following 
clinical suspicion based on an abnormal TRUS (transrectal ultrasound), an elevation in serum 
PSA (prostate specific antigen) levels, an abnormal DRE (digital rectal exam) and a histological 
examination of a prostate tumor from a biopsy. (http://www.cancer.org) Prostate cancer typically 
develops in men over age 50.  It is the second leading cancer in men and it is second only to lung 
cancer in cancer-related deaths (http://cancer.gov).  The American Cancer society suggests that 
annual medical examinations for men include a DRE and a PSA determination.  These 
examinations should begin at age 50 for men with life expectancies of at least 10 years or age 45 
for African-American men and men with a family history of the disease (Bunker et al, 2004).  
In 2005, according to the National Cancer Society, prostate cancer was responsible for 232,090 
new cases with an estimated 30,350 deaths (http://www.seer.cancer.gov).  African-Americans 
are disproportionately affected, experiencing prostate cancer about 60% more often than white 
Americans.  African-American men also present with the highest chance of being diagnosed at 
an advanced stage of prostate cancer and they are more likely to die from prostate cancer than 
any other race/ethnicity of people residing the United States (Freedland et al, 2004).  Both the 
Afro-Caribbean population and African-American population have West African ancestry due to 
the enslavement process that took place throughout the 18th and 19th centuries on both the island 
of Tobago and in the United States.   In fact, African ancestry has been linked to prostate cancer 
among males living throughout the Western Hemisphere (Shea et al, 2002).   
  
In addition to ethnicity, a positive family history can be a significant risk factor for the 
development of prostate cancer (Nieder et al, 2003).  Some families may present a Mendelian 
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pattern of inheritance, Carter et al provided evidence for a familial clustering of prostate cancer 
that they attributed to an autosomal dominant mode of inheritance (Carter et al, 1992), still other 
families will present with an inheritance pattern termed “Familial Prostate Cancer”, whereby 
having as few as one affected relative will contribute to prostate cancer risk (Steinberg et al, 
1990).  Heritable genetic effects have been found in twin studies which were conducted in 
Finland that also support the idea of prostate cancer as a genetically linked disease (Verkasalo et 
al, 1999).  There have been many genes linked with prostate cancer.  These include but are not 
limited to mutations in p53 and retinoblastoma (Skar et al, 1999), MXI 1 gene (Eagle et al, 
1995), CAPB, HPC1/rnaSEL, HOC2/ELAC2, HPCX, MSR1, PCAP, and HPC 20 (Nieder et al, 
2003).  The list of potential candidate genes and their polymorphisms is extensive, but to date 
none reliably explain the ethnic differences in prostate cancer risk.  Many chromosomes have 
been investigated as candidate regions of prostate cancer.  These include but are not limited to 
5q, 7q and 19q, which were located in a genome wide linkage analysis to determine prostate 
cancer aggressiveness (Witte et al, 2000).  African-American men experience the highest death 
rates in prostate cancer,  the National Cancer Institute lists the rate as 68.11 compared to white 
males who have a rate of 27.7 (www.cancer.gov/cancertopics).  Nieder et al, suggested that 
African-American ethnicity is a risk factor for developing prostate cancer (Nieder et al, 2003).   
High serum levels of the cytokine interleukin 6 [IL-6] have also been correlated with 
prostate cancer risk (Nakashima et al, 2000).  Both prostate cancer explants and human prostate 
cancer cell lines secrete IL-6 in vitro (Nakashima et al, 2000).    
This paper will focus on the gene Interleukin 6 Signal Transducer Isoform 1 [IL-6ST], on 
chromosome 5q11.2, with polymorphisms relating to gp130 [figure 2] in exon 10 [rs 3730293] 
                                                 
1 Statistics are for 1998-2002 and are adjusted to the 2000 U.S standard million population, and represent the 
number of deaths per year per 100,000 males. 
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and exon 14 [rs 3729960]; both single nucleotide polymorphisms [snp] result in an amino acid 
change.   
 
Exons                                   name                                       Variation                                          Relative position 
 
Figure 2:  IL6ST gene map and polymorphisms 
Figure taken from http://snpper.chip.org/bio/show-gene/15725
 
These snps were chosen because IL-6 acts through its receptors which are polymorphic, 
and subsequently may cause it to have different functionality.  A complete gene map of the 
polymorphisms of IL6ST can be found in the appendix.  A population based case/control study 
was conducted to evaluate the influence of gp130 snps on prostate cancer risk in an Afro-
Caribbean male population of Tobago. 
 4 
1.1 INTERLEUKIN 6 
Interleukins are cytokines [regulatory proteins secreted by cells] that regulate the interactions 
between lymphocytes and other leukocytes.  They are different from conventional hormones, in 
that they can have effects on numerous different cells (Tizard).  Interleukin 6 [IL-6] can activate 
target genes involved in survival, differentiation, apoptosis and proliferation (Heinrich et al, 
2003).  Various types of malignant tumors have implicated IL-6 as being important to their 
regulation of growth and differentiation; these include renal-cell carcinoma, leukemia and 
prostate tumors (Lou et al, 2000).  Both multiple myeloma and prostate cancer have been 
attributed to the dysregulation of IL-6 cytokine signaling (Heinrich et al, 2003).  In fact, the 
function of IL-6 as it relates to human malignancy is noticeably established in multiple myeloma, 
where tumor growth is aided by autocrine stimulation of IL-6 (Giri et al, 2001).  Chung and 
colleagues, suggest IL-6 can be characterized as a paracrine or autocrine growth factor that is 
implicated in the oncogenic processes of the following tumors: mammary carcinoma, lymphoma, 
plasmacytoma/myeloma and Kaposi’s sarcoma (Chung et al, 1999).  IL-6 may induce growth of 
prostate cancer cells and assist the escape of apoptosis, which would result in an increase in 
disease development through the augmented production of IL-6.   IL-6 is a pleiotropic 21-30kDa 
glycoprotein consisting of 212 amino acids with varying glycosylation (Chung et al, 1999).  It is 
important to note the single presence of IL-6 is not enough for cell mediation.  Human IL-6 
signaling requires the 80kDa IL-6R receptor, which is responsible for IL-6 specificity and the 
130kDa glycoprotein, gp130, the signal transduction subunit for several cytokines, for signal 
transduction to occur (Kishimoto et al, 1992).  Signal transduction is a process that results in the 
delivery of an active transcription factor to the cell’s nucleus in response to cell surface receptor 
binding by an extracelluar protein ligand. 
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Figure 3:  Receptor complexes of IL-6 type cytokines 
(Heinrich, 2003) 
 
When IL-6 binds to its receptor IL6-R, it leads to activation of members of the Janus [JAK] 
kinase family, which in turn phosphorylate tyrosine residues in the cytoplasmic domains of the 
gp130 subunit.  Glycoprotein 130 combines with activators of transcription [STAT factors] to 
undergo tyrosine phosphorylation, dimerization and translocation to the nucleus (Culig et al, 
2002).   In the human body gp130 is expressed ubiquitously and all of the IL-6 type cytokine 
receptor complexes use gp130 as the receptor signaling subunits. These complexes have diverse 
functions and are involved in immune and inflammation responses, liver and neuronal 
regeneration, haematopoiesis, fertility and embryonal development (Heinrich et al, 2003).  It is 
interesting to note that gp130 can also transduce signals from many different ligands.  For 
instance, the following all use gp130 as a signal transducer:  oncostatin M, leukemia inhibitory 
factor, cardiotrophin-1, IL-11, ciliary neurotrophic factor, and cardiotrophin-like cytokine 
(Müller-Newen). 
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Gp130 is a signal transducer and while it is ubiquitous in the normal human cell, the 
ability of gp130 to begin signal transduction appears to be regulated by the restricted expression 
of the ligand binding component.  The ligand binding component for IL-6 is IL-6R.  For this 
reason, recent research examining the potential effects of IL-6 on prostate cancer also looks for 
the presence of IL6R and gp130.  The expression of IL-6 and IL-6R has been found in both 
benign prostate hyperplasia and prostate carcinoma (Lou et al, 2000).  In fact both IL-6R and 
gp130 have been found in four cancer cell lines:  hormone dependent LNCaP, and the hormone 
refractory lines of PC3, DU145 and TSU.   
 
 
 
 
Figure 4:  Detection of mRNA expression for both gp 130 and IL-6R by RT-PCR in cell lines     
(Lou et al, 2000) 
  
 
The presence of the IL-6 in the LNCaP cancer cell line is controversial.  Giri et al, report 
being unable to detect the secretion of IL-6 from LNCaP (Giri et al, 2001).  Chung et al, did not 
find evidence of IL-6 in the LNCaP cancer cell line and attributed it to “different test conditions” 
(Chung et al, 1999).  However they were able to detect soluble forms of both IL-6R and gp130 
by RT-PCR and immunoprecipitation with anti-gp-130 (Chung et al, 1999). 
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1.2 ANDROGEN INDEPENDENCE  
In a normal human prostate epithelial cell, the hormone androgen is responsible for the growth 
and maintenance of the functional and structural integrity of the cell.  The absence of androgen 
will usually result in apoptosis.  Most prostate epithelial cell growth is initially dependent on 
hormonal stimulation and is therefore androgen-dependent.  At this stage, the cells are receptive 
to androgen-ablative therapies.  Androgen-independent prostate cancer cells often escape 
apoptosis and thrive in the new hormone refractory environment (Chung et al, 1999).  In these 
prostate cancer cells, IL-6 may undergo a functional transition from a paracrine growth inhibitor 
to an autocrine growth stimulator (Culig et al, 2002). 
 
1.3 HHV-8 AND IL-6 
According to Koroidi and colleagues, sexually transmitted infections and sexual history have 
been discovered to be significant risk factors in the etiology of prostate cancer (Korodi et al, 
2005).  Among the sexually transmitted viruses is human HHV-8, responsible for the formation 
of Kaposi sarcoma.  HHV-8 is a sexually transmitted, gamma-2 herpesvirus and its presence has 
been reported in both normal and cancerous prostate tissue (Hoffman et al, 2004).  In fact, 
Hoffman et al, reported an association between prostate cancer and HHV-8 (Hoffman et al, 
2004).   
The HHV-8 virus includes a functional homologue of interleukin-6 named vIl-6, but 
unlike IL-6 it does not need the IL-6R subunit to begin signal transduction (Wan et al, 1999).  
This is important because as previously stated gp130 is ubiquitously expressed in the human 
 8 
body.  In a paper by Wan and colleagues, the activation of STAT1 and STAT3 cells in human 
HepG2 hepatoma cells by vIL-6 sans its IL-6R was demonstrated (Wan et al, 1999).  They also 
reported that IL-6 is an important autocrine growth factor for Primary Effusion Lymphoma or 
PEL (Wan et al, 1999).  Chung et al characterized IL-6 as either a paracrine or autocrine growth 
factor that was implicated in the progression of Kaposi sarcoma, it is therefore reasonable to take 
a closer look at HHV-8 (Chung et al, 1999).   
Another paper examined sexually transmitted diseases and prostate cancer risks (Hayes et 
al, 2000). While they did not look specifically at HHV-8 and prostate cancer risks, the authors 
did suggest that an infectious agent may act as a co-factor in the development of prostate cancer.  
HHV-8 could be that co-factor and may act through vIL-6 to increase prostate cancer risk.  
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MATERIAL AND METHODS 
 
1.4 STUDY POPULATION 
Male inhabitants of the island of Tobago were examined for the presence of both prostate cancer 
and gp130 mutations.  Two main islands compose the Republic of Trinidad and Tobago.  Tobago 
is smaller than Trinidad and is located near the southern Caribbean Sea, south of Grenada and 
northwest of the island of Trinidad (http://en.wikipedia.org/wiki/Tobago).   Ninety-two percent 
of the people who inhabit the Caribbean island of Tobago are self-identified as Afro-Caribbean 
(Bunker).  According to the 1990 Census the population was 46,435 of that 5,121 were males 
ages 40-79.   
1000 DNA samples were genotyped for two single nucleotide polymorphisms.  The 
samples were obtained from the Bunker et al. Tobago study (Bunker 2002).  In this study, the 
male population aged 40-79 of Tobago and Trinidad was solicited for participation in a 
population based prostate cancer screening survey. The samples were blinded to the researcher 
and the cancer status of the person was unknown until the time of analysis.  In the analysis the 
samples were broken up into two groups, cases and controls.     
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1.4.1 CANCER DIAGNOSIS- DISTINCTION BETWEEN CASE AND CONTROL 
 
The clinical diagnosis of subjects with prostate cancer was determined by abnormal DRE’s, 
elevated PSA’s and prostate biopsies (Bunker 2002).  Initially peripheral blood draws were done 
and PSA (prostate specific antigen) measurements were taken.  The PSA measurements were 
analyzed at the University of Pittsburgh’s Central Pathology Laboratory using the automated 
Microparticle Enzyme Immunoassay, Abbot AxSYM PSA assay. To avoid artifactual increase in 
serum PSA, the subjects underwent a DRE (digital rectal exam) at a later date.  A physician 
trained according to the Bunker study protocol performed the digital rectal exam.  Subjects with 
an abnormal DRE or whose serum PSA level was found to be elevated (≥ 4.0 ng/ml) were then 
selected for biopsy.  Pathological evaluation of the prostate tissue was performed by either 
urologists or surgeons trained by urologists from the University of Pittsburgh’s Medical Center.  
Using an 18 gauge, 21cm spring-loaded biopsy needle, transrectal ultrasound guided biopsies 
were executed.  Sextant biopsies were acquired in accordance with a standard protocol (Bunker 
2002).  After the evaluations, the men were then labeled as either having prostate cancer or not 
having prostate cancer.  All protocols were both approved and reviewed by the Institutional 
Review Board of the Tobago Ministry of Health and the University of Pittsburgh.  Each 
participant provided written informed consent.  The Bunker et al study found, “The screening 
detected prevalence of prostate cancer in this Afro-Caribbean population, ages 50-79 years was 
about three to four times higher than rates reported from screening studies in predominately 
Caucasian populations.”  The total screened population presented a prostate cancer prevalence 
rate of 10.7% among men aged 40-79 (Bunker et al, 2002).  The samples used in this paper are a 
subset of samples from the Bunker study. 
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 1.5 GENOTYPE ANALYSIS 
To analyze the PSA levels peripheral blood draws were done.  High molecular weight DNA was 
isolated from the residual clots drawn for PSA tests.  Genotype analysis was done by polymerase 
chain reaction and fluorescence polarization.  DNA Engine Dyad and Tetrad 2 machines by 
Peltier Thermal Cycler were used for the PCR [amplification], SAP [incubation] and TDI 
[template directed primer extension] steps.  Fluorescence polarization analysis was done with a 
Criterion Host, Analyst HT machine designed by LJL Biosystems. 
 
1.6 POLYMERASE CHAIN REACTION (PCR) 
The two single nucleotide polymorphisms chosen were rs 3730293 and rs 3729960.  In rs 
3730293 the base pair change is A to G with an amino acid change of Isoleucine to Threonine.  
In rs 3729960 the base pair change is C to G with an amino acid change of Leucine to Valine.   
A total volume of 10μL per reaction composed of water plus the following reagents from 
Invitrogen:  50 mM MgCl2, 10X PCR Buffer, 5U/μl Taq DNA polymerase, 1.25 mM dNTP and 
20μM of forward and reverse primers was used.  The primers and conditions are listed in table 1. 
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Table 1:  Primers and Conditions for SNPs 
 
  Primers   Conditions     
      
  rs 3730293         
Forward 5' CTA GCC AGG TAT ACC TCT 3' step 1 
Initial 
Denaturation  95 °C 5 minutes 
Reverse 
5' GCT ACT CAC CCT GTA ATG GAT 
3' step 2 Denaturation  95 °C 30 sec 
Detection 
5' GAT AAC ACA CAC CAC TCA AGT 
3' step 3 Annealing 47.4 °C 15 sec 
    step 4 Extension 72 °C 30 sec 
    step 5 Repeat step 2 
34 
cycles   
    step 6 Final Extension 72 °C 
10 
minutes 
            
  rs 3729960         
Forward 5' CCA GCA AAA ATG ACT AAC 3' step 1 
Initial 
Denaturation  95 °C 5 minutes 
Reverse 5' GTT GCA TTG TGA ACG AGG 3' step 2 Denaturation  95 °C 30 sec 
Detection 5' CAA GTG TGT TTC CCT TCC AC 3' step 3 Annealing 55 °C 15 sec 
    step 4 Extension 72 °C 30 sec 
    step 5 Repeat step 2 
34 
cycles   
    step 6 Final Extension 72 °C 
10 
minutes 
 
 
 
1.7 FLUORESCENCE POLARIZATION (FP) 
The basis for fluorescence polarization is based on the concept of molecular movement and 
rotation.  By using a fluorescent dye to label a small molecule, its subsequent binding to another 
molecule of equal or greater size can be monitored through its speed of rotation.  This process 
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can determine which allele is present (Chen et al, 1999).  There are two steps in FP, the 
primer/dNTP degradation step with Shrimp Alkaline Phosphatase incubation and the TDI assay 
where the fluorescent dyes are attached.  After dye attachment, the sample was ready for 
fluorescence polarization measurement (Chen et al, 1999).  A total volume of 10μL per reaction 
composed of water plus the following reagents from Invitrogen:  10x SAP buffer, 1 U/μL SAP 
and 10 U/μL exonuclease was used. 
 
Table 2:  Protocol for SAP step 
SAP conditions  
Incubation 37° C 90 minutes 
Denaturation 95° C 15 minutes 
Hold 10° C  
 
After the SAP step gets completed, the TDI assay begins.  A total volume of 10μL per 
reaction composed of water plus the following reagents from Invitrogen:  10x thermosequenase 
buffer, 10μM internal detection primer, 25 μM dye labeled ddNTP mix, and 4U/μL 
thermosequenase was used. 
 
Table 3:  Protocol for TDI step 
TDI conditions  
Denaturation 94° C 1 minute 
Denaturation 94° C 10 sec 
Extension 55° C 30 sec 
Repeat Go to step 2 39 cycles 
Final Extension 72° C 10 minutes 
Hold 10° C  
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RESULTS 
In a population of men from Tobago who were characterized as having high rates of prostate 
cancer, two snps in gp 130 were examined and no evidence of association with prostate cancer 
risk between genotypes or haplotypes was identified.  There were 284 cases and 716 controls of 
which reliable genotypes were obtained for 284 cases and 594 controls in rs 3730293.   In rs 
3729960, genotypes were obtained for 257 cases and 618 controls.   
Failure to genotype was either the result of PCR failure, FP failure or from lack of 
sufficient DNA.  Table 4 shows a summary of observed and expected genotypes for the Tobago 
male population.  A complete list can be found in the appendix section of this paper.   
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Table 4:  Summary of Observed and Expected Genotypes 
 
    
284 
cases      
716 
controls   
rs 
3730293   
n= 
238      n=594   
    observed expected    observed expected 
  AA 122 123.58  AA 275 283
  AG 99 95.84  AG 270 254.01
  GG 17 18.58  GG 49 57
 wild 
type p 0.7206    p 0.6902   
  q 0.2794    q 0.3098   
  χ2 0.26    χ2 2.35   
  
p-
value 0.61    
p-
value 0.12   
               
    
284 
cases      
716 
controls   
rs 
3729960   n=257      n=618   
    observed expected    observed expected 
  CC 66 65.76  CC 183 177.28
  CG 128 128.48  CG 296 307.43
  GG 63 62.76  GG 139 133.28
 wild 
type p 0.5058     p 0.5356   
  q 0.4942     q 0.4644   
  χ2 0     χ2 0.85   
  
p-
value 0.95     
p-
value 0.36   
Key to Base Pairs: 
A= Wild Type      C=Wild Type  
G= Polymorphism     G= Polymorphism  
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1.8 STATISTICAL ANALYSIS 
Hardy Weinberg Equilibrium describes the relationship between allele frequencies and the 
resulting genotypic frequencies.  HWE principles were used to determine the expected number of 
individuals with each genotype.  Allele frequencies were estimated by gene counting.  The 
expected frequencies were then compared to the observed frequencies.  The Chi-square test was 
used to compare the expected allele frequencies to the observed allele frequencies to determine if 
the loci were in Hardy Weinberg Equilibrium [HWE].  These results can be found in table 4. 
The Chi-square test was also used to calculate the homogeneity of the allele or genotype 
frequencies between the cases and controls.  It is used to determine if a significant relationship 
existed between genotypes of the cases versus genotypes of the controls. 
Haploview 3.2 (http://www.broad.mit.edu/mpg/haploview/) was used to calculate if pair wise 
linkage disequilibrium existed between rs 3729960 and rs 3730293.  It can be expressed as D’ 
where D’ is a measure of the strength of association between the alleles at the two loci.  D’ 
equaling 1 is representative of complete linkage disequilibrium.  D’ equaling 0 is representative 
of complete linkage equilibrium.  The results can be found in table 6. 
 
1.9 ALLELE FREQUENCIES 
In rs 3730293 cases, the wild type allele was represented by “A” coding for the amino acid 
Isoleucine.  Its frequency was 0.7206.  The polymorphism was represented by “G” coding for the 
amino acid Threonine.  Its frequency was 0.2794.  Both alleles were found to be within HWE 
with a p-value of 0.61. 
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In rs 3730293 controls, the wild type allele was represented by “A” coding for the amino acid 
Isoleucine.  Its frequency was 0.6902.  The polymorphism was represented by “G” coding for the 
amino acid Threonine.  Its frequency was 0.3098.  Both alleles were found to be within HWE 
with a p-value of 0.12. 
In rs 3729960 cases, the wild type allele was represented by “C” coding for the amino acid 
Glycine.  Its frequency was 0.5058.  The polymorphism was represented by “G” coding for the 
amino acid Arginine.  Its frequency was 0.4942.  Both alleles were found to be within HWE with 
a p-value of 0.95. 
In rs 3729960 controls, the wild type allele was represented by “C” coding for the amino acid 
Glycine.  Its frequency was 0.5356.  The polymorphism was represented by “G” coding for the 
amino acid Arginine.  Its frequency was 0.4644.  Both alleles were found to be within HWE with 
a p-value of 0.36. 
 
 
Table 5:  Chi-Square Table for Cases and Controls 
rs 3730293 
 AA AG GG Total
Cases 122 99 17 238 
Controls 275 270 49 594 
Total 397 369 66 832 
 
rs3729960 
 CC CG GG Total
Cases 66 128 63 257 
Controls 183 296 139 618 
Total 249 424 202 875 
AA & CC represent the wild type alleles 
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In rs 3730293 no significant relationship was found for the genotypes of the cases compared to 
those of the controls.  The Chi-square value was 1.71 with an insignificant p-value. 
In rs 3729960 no significant relationship was found for the genotypes of the cases compared to 
those of the controls.  The Chi-square value was 1.44 with an insignificant p-value. 
                                           Table 6:  Linkage Disequilibrium Values 
 
Haploview 
Data  
D' 0.9 
LOD 83.19
r-
squared 0.357
 
Linkage Disequilibrium describes a situation in which some combination of AA, AG, GG and 
CC, CG, GG alleles occur more frequently in the Tobago population than would be expected 
from this random formation.  The Haploview program yielded D’ = 0.9 indicating that strong 
linkage disequilibrium was present for rs 3730293 and rs 3729960 in the Tobago population.   
 
 
 
 
 
 
 
 
 
 
 19 
DISCUSSION 
Genotype analysis of two polymorphisms in gp130 (rs 3730293 and rs 3729960) in the prostate 
cancer susceptibility gene IL6ST suggests that the polymorphisms do not significantly contribute 
to the increased risk of prostate cancer as observed in the case/control population of Tobago. No 
significant increased or decreased risk for prostate cancer was detected among men carrying the 
variant genotype.  It is worthy to state that the International HapMap Project reports 
monomorphic allele frequencies for rs37302932 in Japanese, Chinese and Utah, U.S populations.  
Only the Nigerian population presented polymorphic allele frequencies.  The Japanese samples 
were taken from a population in Tokyo, the Chinese samples were taken from a population in 
Beijing, and the Utah population was composed of residents with ancestry from northern and 
western Europe.  The Ibadan population of Nigeria has allele frequencies very similar to those 
obtained in this paper.  HapMap lists them as the wild type allele A=0.617 and the mutated allele 
G= 0.383.  The polymorphic nature of these alleles may act in conjunction with other genes or 
may have different functionality that may have contribute toward prostate cancer risk.  The 
discrepancy in the incidence of prostate cancer according to geographic region and ethnicity is 
very interesting.  Prostate cancer rates in Asian countries are low.  In comparison to the United 
States, countries like Japan and China have prostate cancer rates that are 50-60 times lower 
(Hsing et al, 2000). Further more the rate of prostate cancer for Caucasians in the United States 
                                                 
2 No allele frequency information was given for the rs 3729960 polymorphism in either the HapMap database or in 
the National Center for Biotechnology Information [NCBI] database 
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is sixty percent less than the rate of African-Americans; although it has been postulated that 
prostate cancer rates will increase in countries that previously held low rates due to aging 
populations and increased PSA screening (Hsing et al, 2000).   
To find a link to prostate cancer risk it will be necessary to look at more than just the snp’s listed 
in this paper. While it is believed that IL-6 is a good gene to examine for prostate cancer risk, a 
paper by Sun et al,  found some sequence variants of IL-6 that were not associated with prostate 
cancer risk (Sun et al, 2004).  However, those authors did not examine snps relating to 
glycoprotein 130.   
Conflicting research was also found for HHV-8.  In a nested case/control study done in Finland 
by Korodi et al, it was suggested that selection bias may have been present in the Hoffman et al 
paper.  They reported evidence against involvement of both HHV-8 and HSV-2 in prostate 
carcinogenesis (Korodi et al, 2005). 
 
1.10 FUTURE STUDIES 
Prostate Cancer and cancers in general continue to be responsible for illness and death in 
populations all over the world.  Populations with West African ancestry are particularly 
susceptible to prostate cancer.  While the polymorphisms examined in this paper yielded no 
significant association to prostate cancer, it is important to keep looking.  IL-6 has been 
implicated in a number of studies and more polymorphisms should be identified and researched 
as potential risks to prostate cancer.  It would have been useful to redo this study in another 
population of men with West African ancestry.  The future study should include HHV-8 
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seroprevalence data and examine more snps in IL6ST particularly looking at functionality with a 
more detailed haplotype analysis. 
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CONCLUSION 
Research of the two polymorphisms in Interleukin-6 Signal Transducer Isoform 1 did not yield 
any significant association to prostate cancer risk.  While the genotypes were in HWE for all 
alleles of both the case and control groups, no strong conclusions could be drawn.  Further 
research is needed. 
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Appendix A 
GENOTYPES OF TOBAGO STUDY POPULATION 
ID Number 
PC 
status 
rs 
3729960 rs3730293   ID Number 
PC 
status 
rs 
3729960 rs3730293
TP970002CJ control CG AA   TP991123VP control   AG 
TP970008DP control GG AG   TP991125DM case CG AA 
TP970009HP control CG AG   TP991127AM control GG AA 
TP970013LM case GG AG   TP991137WF case GG GG 
TP970014PB control CC AA   TP991139EC control CC AA 
TP970017CG control GG GG   TP991140JB case GG AG 
TP970022DH case CC     TP991143SR case GG AG 
TP970024JM control CC AA   TP991146AT control   AA 
TP970025WR control CG AG   TP991148AR control CC   
TP970028VR control CC AA   TP991149JW control CG AG 
TP970029HA control CC     TP991150CB control   AA 
TP970030ME control CG AG   TP991152AT control CC AA 
TP970033FG control CG AG   TP991155RS control CC   
TP970035AM case CC AA   TP991159AA control CG AA 
TP970037FC control GG AG   TP991163EA control GG AG 
TP970040AP control CG AG   TP991166CN case CG AA 
TP970042WR control CG AG   TP991170GK control CG AG 
TP970043NH control CC AA   TP991181MC control CG AG 
TP970045FD control GG AG   TP991182GD control GG AG 
TP970046RH case CG AA   TP991186CB control CC   
TP970048PR case GG AG   TP991188CS case GG AG 
TP970049PP case CC AA   TP991191LJ case CG AG 
TP970052OD case GG     TP991195GS control CG AA 
TP970053SD control CG     TP991196VR control GG AG 
TP970054LR control   AA   TP991197MD case GG AG 
TP970056WT control CG AG   TP991198WB case GG AA 
TP970058HE control CC AA   TP991199BC control CG AG 
TP970059GW control CG AG   TP991200OB case CC AA 
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TP970060LC control CC AA   TP991204JA control CG AA 
TP970061JL control GG AG   TP991205ST control CG AG 
TP970063HP control CG AG   TP991207HR control CG AA 
TP970064AD control   GG   TP991208EB control GG AA 
TP970065GR control CC AA   TP991209EA control CG AA 
TP970066LC control CG AA   TP991210WG case CG AA 
TP970067CL control CG AA   TP991211LT control GG AG 
TP970068CN case CG AA   TP991215CB control CG AG 
TP970069GA control GG AG   TP991217OB control CG AG 
TP970071EA control CG AG   TP991219RJ control CC AA 
TP970077AR case CG AA   TP991221KG control CC AA 
TP970078JR control CG AG   TP991224JR case CC AA 
TP970079RM control CC AA   TP991225RS case CG AG 
TP970080AS control CG AG   TP991227EC control CC AA 
TP970082RJ case CG AA   TP991230HS control CG AG 
TP970083RA control CC AA   TP991233WW control CG AA 
TP970084HG case CG AG   TP991234RL case GG AG 
TP970085SS control CG AA   TP991235UG case CC AA 
TP970086GT case CC AA   TP991237SG control CG AG 
TP970087HL control GG GG   TP991242RD control CG AA 
TP970088ED control CC AA   TP991243RM control CC AA 
TP970089ED control CG     TP991244GP control CG AA 
TP970090JR case CC AA   TP991245AB control GG AA 
TP970091AM case CG AG   TP991246MJ control CG AG 
TP970094SB control GG AA   TP991249JT control   AA 
TP970095ND control CC AA   TP991250AB control CC AA 
TP970097CT control CC AG   TP991255RQ control CG AG 
TP970098AT case GG GG   TP991259NS control CG AG 
TP970099RS control CG AG   TP991260CJ case CG AA 
TP970103DM case GG AG   TP991263DD control   AA 
TP970106WC control GG AG   TP991267FS case   AA 
TP970107CD control CG AG   TP991269AB control GG AG 
TP970108JR control CC AA   TP991273AF control CG AA 
TP970109TP case CG AG   TP991274EJ case CG AG 
TP970112OS case CC AA   TP991276NR control CG AA 
TP970113HT control CC     TP991278SB control GG AG 
TP970115EM control CG AG   TP991283HE control CC AA 
TP970119CA case CG AG   TP991284PJ control CC AA 
TP970123VW control CG AA   TP991286CP control CG AG 
TP970126RC control CG AG   TP991289DB control CG AA 
TP970127EP control   AA   TP991290LK case CG AG 
TP970130FK control CC AA   TP991291LT case GG AA 
TP970132KM control CG     TP991292CP control GG AG 
TP970134JG control GG AA   TP991293UL control   AG 
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TP970135HC control CG AG   TP991296LT case GG AA 
TP970137HO control CG AG   TP991301SR control CG AG 
TP970138FP control CG AG   TP991303CC control CG   
TP970139GP control CG AA   TP991305BC control CG AG 
TP970140DS case GG GG   TP991306SP control CC AA 
TP970141AR control GG AG   TP991307LS control CG AA 
TP970145VD control CG     TP991308PJ control CG AG 
TP970146SD control GG GG   TP991309KW control CC AA 
TP970151AC control GG AG   TP991312WD control CG   
TP970152AT control CG AG   TP991318CS control CG AG 
TP970153NB control CG AG   TP991319LA control CC AA 
TP970155CW control CG AG   TP991325CP control CC AA 
TP970158CC control GG     TP991326DL control CG AG 
TP970160GG case CG AA   TP991330AD control GG GG 
TP970161JD control CG AG   TP991331RC case CG AA 
TP970162IL control GG GG   TP991339SG case CG AG 
TP970163JQ control CG AG   TP991340DW case GG   
TP970165CO case CC AG   TP991346HB control GG AA 
TP970167CB case CG AA   TP991348GB control CC AA 
TP970169LG case CG AG   TP991352HM control GG AG 
TP970170FR control CG AG   TP991356RM control CG AG 
TP970171JW control GG AG   TP991357CH control CG AG 
TP980173CI control CG AG   TP991359SC case GG GG 
TP980180WJ control CG AA   TP991362HB control CG AA 
TP980182WW case CC AA   TP991366JM case CG AG 
TP980184JM case GG AA   TP991367CM case GG GG 
TP980185PJ control CG AG   TP991370KC control GG GG 
TP980187AC control CG AA   TP991372MJ case GG AG 
TP980188AJ control CC AA   TP991377DP control CG AA 
TP980189MG control GG AA   TP991378DS control CC AA 
TP980193CP control CC AA   TP991379SA control CC AA 
TP980194CR case CG AA   TP991384AF case CG   
TP980195FD control CC AA   TP991385HB control   AG 
TP980198JQ control CG AG   TP991389CG case GG AA 
TP980199HW control GG GG   TP991392TB case   AG 
TP980200HJ control CC AA   TP991397SB control GG   
TP980201LC case CC AA   TP991398LH control CC   
TP980202WP control CC AA   TP991402MT control GG GG 
TP980206CC control CG AG   TP991405AT case CG AG 
TP980207NF control CG AG   TP991406RS case CC AA 
TP980210CT control CC AA   TP991408MC case CG AG 
TP980212SD control CC AA   TP991411DL control GG AG 
TP980214HL control CG AG   TP991412EC case CG AA 
TP980217HP control CC AA   TP991419PG control GG   
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TP980218AD case CC AA   TP991423CJ case GG AG 
TP980221WR control CC AA   TP991424IA control GG GG 
TP980222HC control GG AG   TP991427BP control CG AG 
TP980224NM control CC AA   TP991439JP case   AA 
TP980225VS control GG AG   TP991440NT case CC   
TP980226AJ control CC AG   TP991441VB control GG AG 
TP980227IA control CC AA   TP991442WC case CG AG 
TP980228WA control CC AA   TP991447KT control CG AG 
TP980230SC case CC AA   TP991449DL control GG AG 
TP980233KC control CC AA   TP991455EW case GG AA 
TP980234AB control CC AG   TP991456TM control CG AG 
TP980235MW case CC AA   TP991463RW control GG GG 
TP980241ET control CC AA   TP991466MT control   AA 
TP980250NB control GG AG   TP991467GR control   AA 
TP980252KS control CC AA   TP991475DQ control CG AG 
TP980254HA case CG AG   TP991490FJ control CC AA 
TP980258RE control CC AA   TP991495HP control GG   
TP980262RH control GG AG   TP991496EG control CG AG 
TP980263AW case CC AA   TP991497AB case CG   
TP980264AT control CC     TP991500RO control GG   
TP980265DP control   AG   TP991506HA control GG   
TP980266CT control CG AG   TP991510ES control GG AG 
TP980269SC control CC AG   TP991514KK case CG   
TP980271JM control CG AG   TP991515CF control CG AG 
TP980272TR case GG AG   TP991518TB control     
TP980276JJ control CG     TP991521MK case     
TP980280FC control CG AA   TP991522JW control     
TP980281FS case GG AG   TP991525AB control     
TP980282TJ case CG AA   TP991526IH case     
TP980283JG control CC AA   TP991534KN control     
TP980287GJ control CC AA   TP991539ES control     
TP980289LP case CG AG   TP991542WR control     
TP980292NG control CG AA   TP991545LN control     
TP980293HT case CC AA   TP991553EP control     
TP980297JM control CC AG   TP991557HJ case     
TP980298DA control CG AA   TP991559HL control     
TP980307CE control CC AA   TP991565HG control     
TP980309CD control GG AG   TP991581BD control     
TP980310AT case CC AA   TP991584FC control     
TP980313JG control CG AG   TP991587DW control     
TP980322JM control CC AA   TP991588AJ case     
TP980323SB case CC AA   TP991592AT control     
TP980324TL control CC AA   TP991594LG control     
TP980329TS control CC AA   TP991599HB control     
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TP980331AP control CG AG   TP991601EN control     
TP980332LB case GG AG   TP991604RP control     
TP980334WA case CG AA   TP991605IP control     
TP980336ET control CG     TP991607DH control     
TP980337DD control CC AA   TP991612CA control     
TP980339DC control CC AA   TP991615NC control     
TP980341PP case CG AG   TP991618JL case     
TP980342RG control CG AG   TP991619EP control     
TP980346JJ control CC AG   TP991621RJ control     
TP980348JA control GG AG   TP991628VT case     
TP980350SP control CC AA   TP991631CC control     
TP980351FJ control CC AA   TP991632CP control     
TP980354AP control CG AA   TP991633DD control     
TP980357HH control GG AG   TP991634HJ control     
TP980358AP control CC AA   TP991638IC control     
TP980360SW case GG AG   TP991644CM control     
TP980361CC control CG AA   TP991645EM case     
TP980367JR control GG AG   TP991649FM control     
TP980370WG control CG AG   TP991651CD control     
TP980372NA control CG AA   TP991655GD control     
TP980377JT control GG     TP991656RC case     
TP980378GH control CG AA   TP991663PD control     
TP980381GB case CG AA   TP991664NM control     
TP980382HT control CC AA   TP991668GD control     
TP980383AM case CC AA   TP991673WM control     
TP980385TB case GG AG   TP991679KT control     
TP980387SM control CC AG   TP991688OW control     
TP980388HP control CC AA   TP991699ST control     
TP980391DJ control GG AA   TP991719TS control     
TP980393LA control CG AG   TP991720PC control     
TP980395HJ control CC AA   TP991721GM control     
TP980396JS control CG AA   TP991722RD control     
TP980398PW control CG AA   TP991725SH control     
TP980401HS case CG AA   TP991729CM control     
TP980405VC control CC AA   TP991737IA control     
TP980406HC case CC AA   TP991738LM control     
TP980407SC control CG AG   TP991741WR control     
TP980408JW control CG AG   TP991743CR control     
TP980410DP control CG AG   TP991751PJ control     
TP980412JJ control CC AA   TP991756EA control     
TP980413LW case GG GG   TP991761TH control     
TP980416CH control GG AG   TP991762SB control     
TP980422MM control CG AA   TP991795AJ control     
TP980423SW control CG AG   TP991807AL control     
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TP980424LJ control CC AA   TP991809BA control CG   
TP980425SF control CG AG   TP991869MQ case CC AA 
TP980427JD case CC AA   TP991897JL control GG AG 
TP980429JH control CG AG   TP991901ML control CG AA 
TP980431JR control CG AG   TP991902VG case CC   
TP980433RD control GG AG   TP991912RE control CC AG 
TP980434GP control CG AA   TP991916JL control CC AA 
TP980435CJ control CG AG   TP991917TM case CG   
TP980436SS control GG GG   TP991918JM case CG AA 
TP980437TJ control CG AG   TP991939WK case CG   
TP980438JP control   AA   TP991947GC control CC AA 
TP980440GB case CG AA   TP991952CM control GG AG 
TP980442ET control CG AG   TP991959GH control CC AA 
TP980444HA case CG AA   TP991963HS control CG AA 
TP980446DB case CC AA   TP991974LQ control CG AA 
TP980447HM case CG A   TP991979JP control CG AA 
TP980448LD control CC AA   TP991980TC control GG AA 
TP980449MJ case CC AA   TP991990TR case   AA 
TP980450CR control CG AA   TP991997ED case CG AG 
TP980453HD control GG GG   TP992002VK case CG AG 
TP980454HW case CG AG   TP992007CK case CG   
TP980458CM control GG AG   TP992009WM case GG   
TP980460UC control CG AA   TP992012RB control GG AG 
TP980461JE control   GG   TP992022MB case CC   
TP980467CP control CC AA   TP992023SC control CG AG 
TP980468PJ case CG AG   TP992036CS case CG AA 
TP980476AG case GG AG   TP992041RJ control CG AG 
TP980485BA case CG AG   TP992043LT control CC AG 
TP980486IL control GG GG   TP992045TG control GG GG 
TP980488KA control CG AA   TP992047GK control CG AG 
TP980490AJ control CG AG   TP992048AL control CG AG 
TP980492CE control GG AG   TP992050CS control CG   
TP980497RB case CC AA   TP992051CJ control GG AG 
TP980498ST control CC AA   TP992056MP case CG AA 
TP980499LQ case CC AA   TP992058GA case CG AG 
TP980500IT case CG AG   TP992060SM control GG AG 
TP980501LJ control CG AG   TP992061ED control CC AA 
TP980502WP control CC AA   TP992062CG case CG AA 
TP980503CG control CG     TP992063ED case CG AG 
TP980506WJ case CG AG   TP992064AT control CC AA 
TP990508OC control CC AA   TP992071NB case GG AG 
TP990509DG case CC AA   TP992072LB case GG AA 
TP990510PA control CG AG   TP992073VC control CG AA 
TP990512HK case CC AA   TP992075AM control CG AG 
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TP990517GH case CG AG   TP992078BP control   AA 
TP990518FC case GG GG   TP992084GF case CG   
TP990522HM control CG AG   TP992087DW case CG   
TP990523GS case CC AA   TP992095GB case CG   
TP990524SR control CG AA   TP992097DR control CC AA 
TP990526JO control CG AG   TP992101LS case CG AG 
TP990528JG control CC AA   TP992147DT case GG AG 
TP990530OD case GG AG   TP992158TP control GG AG 
TP990532LV control CC AA   TP992165EW case GG   
TP990537CA case CG AG   TP992167CW case GG   
TP990538RJ control CG AG   TP992191AR control CG AG 
TP990540OM control CG     TP992195EP control CG AG 
TP990541IJ control CG AG   TP992204SC case CG   
TP990542OA control CG AG   TP992207WA control CG AA 
TP990549CB control CG AA   TP992208WC case CG   
TP990551IC control GG AG   TP992209RS control CG AA 
TP990552SP control CC AA   TP992212MN control CG   
TP990553ER control GG AG   TP992214HC case GG   
TP990555LA control       TP992228MC control CG AA 
TP990561CC control CG AA   TP992233CR case CC   
TP990562GW case CC AA   TP992241CH control GG AA 
TP990563VS control CC AA   TP992242FS case CC AA 
TP990564DB control CG AG   TP992246RC case CG AG 
TP990565CM control CG AG   TP992260DK control CG AG 
TP990566PS control CC AA   TP992267EB control CC AG 
TP990568VJ control       TP992275DT case CG AA 
TP990572AC control CG AG   TP992281RD case GG AA 
TP990573CG case CG AG   TP992295JB control CG AA 
TP990574BL control CG AA   TP992297SB case CC   
TP990575FM control GG GG   TP992303ET control CC AA 
TP990576VJ control CG AA   TP992306EG case CC AA 
TP990577NL control CG     TP992308KG control GG GG 
TP990578AM control GG GG   TP992309GB control GG AA 
TP990579NM control CG AA   TP992313ED control CC AG 
TP990581LK case GG GG   TP992316HL control CC AG 
TP990582EA control CG AA   TP992317EA control CC AA 
TP990584CB case CG     TP992323HC case   AA 
TP990585SD control CG AA   TP992341CJ case GG   
TP990586JJ case CG AG   TP992346ES control CG AA 
TP990589JP case   GG   TP992359NS case CG AA 
TP990591CT control CG AG   TP992360HW control CG   
TP990595AM control CG AG   TP992366SS control GG AA 
TP990598AJ control   AA   TP992377JJ control CG AG 
TP990602AD control GG     TP992379KJ case CG AA 
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TP990603RM control CG AG   TP992381ET control GG AG 
TP990604KR control GG GG   TP992387JA control CC AA 
TP990605SD control CG AA   TP992389CW control GG AA 
TP990607JS control CG AG   TP992392AC control CC AG 
TP990608BI control CG AG   TP992395WH control GG GG 
TP990609CH control CC AA   TP992396RP control CG AG 
TP990611SG control CC AA   TP992397JG control CG AG 
TP990612CF control CC AA   TP992403LB control CG   
TP990616EF case CC AA   TP992406JM control CC AG 
TP990617ES case CG AG   TP992407EG control CG AA 
TP990618SR control CG AA   TP992414TC control GG AG 
TP990619CB control CG AG   TP992420KW control   AG 
TP990623AR case GG AG   TP992431CW control GG GG 
TP990624CJ control CG AA   TP992433AK control CG AG 
TP990625HR case GG GG   TP992439VN case   AA 
TP990626SM control CC AA   TP992441HJ control CC AA 
TP990630FD control GG AG   TP992442CK control CC AG 
TP990631JJ control CG     TP992444AG control CG AG 
TP990632CK control   AA   TP992446DW control CG AG 
TP990633MA case CC AA   TP992455TW control GG GG 
TP990634CG control CG AA   TP992456HQ control GG AG 
TP990635AS control CG AA   TP992459RG case CG AA 
TP990636FK control CG AA   TP992460FK control CG AA 
TP990637JW control CG AG   TP992461CR control CG AA 
TP990638LS control CC AA   TP992462JD control GG AG 
TP990641MD control CG AA   TP992463OT control   GG 
TP990643DB case CG AA   TP992465TF case CC AA 
TP990645AB control CC AA   TP992470NH control GG AG 
TP990646NG control GG GG   TP992471LM control CG AA 
TP990649MW control CG     TP992472PT control   AA 
TP990650BS control CC AA   TP992475WS case CC AA 
TP990651JA control GG GG   TP992476PD case CC AA 
TP990654CH case CG AA   TP992477GC case CG AG 
TP990655HS control CG AG   TP992479WB case CC AA 
TP990656ER control CG AG   TP992482IB control CG AA 
TP990657BH case CG AA   TP992485JG control CG AG 
TP990658JA control CG AA   TP992488CW control GG GG 
TP990659GW control   AA   TP992489AC control CG AA 
TP990660KW control CG AG   TP992491CA control CC AA 
TP990661RM control GG GG   TP992492MM control CC AA 
TP990662CJ control CC AA   TP992493AB control   AG 
TP990663AH control CC AA   TP992495JA control GG AA 
TP990665DS control GG AG   TP992497NP control CC AG 
TP990666WS case       TP992498IB case CG   
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TP990670WW control CG AG   TP992532EC case GG GG 
TP990671ER control CG AG   TP992576AA control   GG 
TP990672JB control   AA   TP992579AS control GG AA 
TP990673AT control   AG   TP992581HM control CG   
TP990678VA control CG AG   TP992582RD control GG GG 
TP990679BF case CG AG   TP992592LT control GG AG 
TP990680LP control GG GG   TP992595EC control CG   
TP990682TS case CG AA   TP992598MC control GG GG 
TP990686FC case GG GG   TP992599VO control CG AA 
TP990687LT case CC AA   TP992601JD control CG   
TP990689AJ control CG AA   TP992603JN control CG AG 
TP990690FW control CC AA   TP992606ME control CG AA 
TP990694SJ control CG     TP992612HP control   AG 
TP990695EW case CC AA   TP992618HC control CC AG 
TP990696CW control CC AA   TP992622BW control CG AG 
TP990697AH case GG AG   TP992623BW control CC AG 
TP990698EM control CC AA   TP992624LW case CG AA 
TP990699GH control CC AA   TP992628KB control CG AA 
TP990703TP case GG AA   TP992631FB case CC AA 
TP990710NC case CG AG   TP992633BL case CG AA 
TP990713JT case CG AA   TP992634BO control CG AG 
TP990714CB control GG AG   TP992636MG control CG AG 
TP990715HA control CC AA   TP992637WM control CC AG 
TP990719OP control CG AG   TP992640CD control CG AG 
TP990722FM control CC AA   TP992641CW control CC AA 
TP990723HD case CC AA   TP992644RM control GG AG 
TP990727SC control   AG   TP992645SW case CG AG 
TP990731HS control CC AA   TP992650NC case   AG 
TP990733TH control CC AA   TP992701NP control CG AG 
TP990735AC case CG AG   TP992704KM control GG AA 
TP990740AH case CC AA   TP992707SW control GG AG 
TP990741DH control CC AA   TP992708AW control CG AG 
TP990742AS control CG AG   TP992709RW control GG AA 
TP990744UK control       TP992710FW control   AA 
TP990747JR control CG AG   TP992717AM control CC AA 
TP990748CB control CG AG   TP992719BM case CC AA 
TP990749RJ control CG     TP992722CS control GG AA 
TP990751LM control CG AA   TP992724CP control CC AG 
TP990752MW case GG GG   TP992725LT case CG AA 
TP990754DS control CG AA   TP992728AA control CC AA 
TP990757MN case CC AA   TP992732UD case   AA 
TP990761MB case CG AG   TP992741FR case   AG 
TP990773RF case CG AG   TP992770GW control CC AA 
TP990774NF control CC AA   TP992779TJ control CC AA 
 32 
TP990780GS case CG AG   TP992800PW control CC AA 
TP990782CK control CC AA   TP992804SJ control GG GG 
TP990783SM control CG AG   TP992808CA case CG AG 
TP990785KS control CG AG   TP992822VR case   AA 
TP990786AJ control CG AG   TP992824HG case CG AG 
TP990787FM control CG AG   TP992825JW case   AA 
TP990789DL case CG AG   TP992832EB case     
TP990791AA control CG AA   TP992852AS control CC AG 
TP990792AR case CG AG   TP992855GB case   AA 
TP990793RL case CC AA   TP992861ET control CG AG 
TP990796LG case CG AG   TP992864HT case   AA 
TP990797UA case GG AG   TP992866JR control CG AA 
TP990798FO control GG     TP992868IW control GG GG 
TP990801HR case CG AA   TP992870RK case CG AG 
TP990803GM control CG AG   TP992871WL control GG GG 
TP990805GB control GG AG   TP992874LA control GG GG 
TP990808WG control CG AA   TP992877JE control CC AG 
TP990810GL case CG AG   TP992880CL case CG AG 
TP990816KC control CG AG   TP992882ES case GG   
TP990819TN control GG AG   TP992885MM control GG   
TP990826MC case CG AA   TP992886KT control CG AG 
TP990827RC control CC     TP992894RS control CC AA 
TP990828NC control CC AA   TP992898HA control GG GG 
TP990830NN control CG AA   TP992899SG control CC AA 
TP990835WM control CC AA   TP992904HM control CC AA 
TP990837CL case GG AG   TP992906LM control   AG 
TP990841WW control CG AA   TP992911AG case   AG 
TP990844LT control CG AA   TP992913CE control CG AG 
TP990845IM control CG AG   TP992914AJ control GG GG 
TP990848FM control GG     TP992923HD control CG AA 
TP990851WP control CG AG   TP992925AH control     
TP990853IS control CG AG   TP992927GJ control CC AA 
TP990854TW control CC AA   TP992934OM control GG AG 
TP990855RC control CC AA   TP992936PB case CG AG 
TP990856ES control CG AG   TP992938JQ control CG AG 
TP990857EJ case GG     TP992941BA control CC AA 
TP990858MN control GG GG   TP992944MJ control CG AG 
TP990861LM control CG AG   TP992946RC control   AG 
TP990862JB case CC AA   TP992950CA control CG AG 
TP990864AF case CC AA   TP992951PC control CG   
TP990869AC control CC AA   TP992953VW control GG   
TP990871CJ case GG     TP992954SS control CG AA 
TP990879LM case CC AA   TP992955IM control CG AG 
TP990883EM case CC AA   TP992957CO control CC AA 
 33 
TP990885AN case CG AG   TP992961PI control CG AG 
TP990889AN control CG AG   TP992964DW control     
TP990898SB control CG AG   TP992965RB control CC AA 
TP990900JJ control CG AG   TP992967AS case CC AA 
TP990902HR case   AA   TP992972ES case CG   
TP990903CM case CG AG   TP992975HG case CG AG 
TP990907HB control CG AG   TP992976CE case CG AG 
TP990908VT control CC AA   TP992977HK control CG AA 
TP990911EB control CG AA   TP992981HM control CG AG 
TP990912HJ case GG AG   TP992987LD case GG GG 
TP990920JJ control CC AA   TP992988DA control CG AG 
TP990923CN control CG AA   TP992989WB control CG AG 
TP990924ET control CG AG   TP992992BK control CG AG 
TP990929GD case CG AA   TP992996FA control GG AG 
TP990933SD case   AG   TP993000LB case GG GG 
TP990934EJ control CG AG   TP993003RW control CC   
TP990936AT control GG AG   TP993005JP case CG AG 
TP990937PD control CG AA   TP993019BM case CG   
TP990938GB control CG     TP993022RP control CC   
TP990940CC control CG AG   TP993052AA case CC AA 
TP990941GS control CG AG   TP993071TD case CG   
TP990944CA control GG GG   TP993097RB case CG   
TP990946AT case CG AG   TP993100NN case CG AG 
TP990952LG control CC AA   TP993101FP case CG AG 
TP990954CW control   GG   TP993118WJ case CC AA 
TP990956CA control CG AG   TP993142GG control CG AG 
TP990957WP control GG AA   TP993149ND control CG   
TP990959RC control CC AA   TP993150RV control GG AG 
TP990967AC control CG AA   TP993151SJ control CG AG 
TP990971SJ case CC AA   TP993152DC case CC   
TP990976FC control GG GG   TP993154RC control CG AG 
TP990991CO control CG AA   TP993159WT control CC AA 
TP991008RF control CG AA   TP993160HT control CC   
TP991011DS control CG AA   TP993163CR control CG AG 
TP991012CJ case GG GG   TP993164VR control CG AG 
TP991014CM case CG AG   TP993165ED case GG   
TP991015CW case CG AG   TP993171ES control GG   
TP991016CM control CC AA   TP993175FB control CC   
TP991020VT case CC AA   TP993178AM control CC   
TP991025CC control GG GG   TP993184MA control CC   
TP991027IW control CG AG   TP993185CR control GG   
TP991033CS case CG AA   TP993186CC control     
TP991038TN control CC AA   TP993187WW case CG AG 
TP991039GO control CG AG   TP993188SG control GG   
 34 
TP991041HC control CG AG   TP993191ET control CC AA 
TP991043JI control CG AG   TP993194NR case CG AA 
TP991044CR control       TP993196SH case GG GG 
TP991047KP control CG AG   TP993197MM control CC AG 
TP991048CG control GG GG   TP993198RR control CC AG 
TP991054DS control CC AA   TP993202EC case CG AA 
TP991056NJ control CG AG   TP993203BB control CG AG 
TP991057CS control GG GG   TP993205CR control CC AA 
TP991058WC case CG AA   TP993206JB case CG   
TP991059RA case GG AG   TP993239LC case CG AA 
TP991060ED control GG GG   TP993246MN case CG AG 
TP991061AS control CG AG   TP993262MP control CC   
TP991063AD control CG AA   TP993269DR control GG AA 
TP991065VM control CC AA   TP993273AA control CG GG 
TP991069ME control CC AA   TP993285KD control CC AG 
TP991070LG control CG AA   TP993299NC case GG AA 
TP991074SG control CG AA   TP993308MG case CG AG 
TP991075CG control       TP993314EP control GG AA 
TP991077MW case CG AG   TP993316CC case CG AA 
TP991080AH control CC AA   TP993319EB control CG AA 
TP991081VJ control CG AG   TP993325OC control CG   
TP991084OM control CG AG   TP993326WH control CG AA 
TP991090VL case CC AA   TP993330RR case CG AA 
TP991093SJ case GG AG   TP993331GB control GG AA 
TP991097FW control CC AA   TP993333RR control CC AG 
TP991098FB control   AG   TP993334DP control CC AG 
TP991099KJ control GG GG   TP993336HS control CC AA 
TP991103KC control CC AA   TP993339EB control     
TP991105PY control GG AA   TP993358RH case CC AG 
TP991107CD control CG AA   TP993359EW control CC AG 
TP991114CC control CG AG   TP993367RR control GG GG 
TP991116NM control CC AA   TP993368LW case CC AG 
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